EUCTR2004-005068-26-DK进行中（未招募）不适用
A Phase 2 Study of Oral Enzastaurin HCl in Patients with Metastatic Colorectal Cancer - N/A
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1]Have histologically or cytologically documented adenocarcinoma of the colon or rectum.
- •[2]Have Stage 4 disease that is not amenable to regimens with curative intent (including surgery and chemotherapy).
- •[3]Have not received prior systemic chemotherapy for advanced CRC (prior adjuvant therapy is allowed).
- •[4]Have given written informed consent.
- •[5]Have the presence of at least one measurable lesion, as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) (refer to Protocol Attachment JCAR.4).
- •[6]Have a performance status of 0 to 1 on the ECOG Scale and no physical tumor symptoms (refer to Protocol Attachment JCAR.2).
- •[7]Have completed all previous radiation therapy and surgical procedures for cancer at least 30 days prior to study entry and recovered from all effects of these therapies.
- •[8]Exhibit patient compliance and geographic proximity that allow for adequate follow-up.
- •[9]Have adequate bone marrow reserve and organ function as follows:?Neutrophil count to > 1.0 x 109/L and platelets > 100 x 109/L.·Hepatic: total bilirubin <1.2 times ULN; alkaline phosphatase <1.5 times ULN; alanine transaminase (ALT) and aspartate transaminase (AST) <2.0 times ULN (or <3.0 times ULN in case of known liver involvement). LDH must be <1.5 times ULN.
- •[10]Reproductive potential must be either terminated (by surgery, radiation, or menopause) or attenuated by the use of an approved contraceptive method (including intrauterine or barrier devices) during and for 3 to 6 months following the study.
- •[11]Are at least 19 years of age.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients will be excluded from the study if they meet any of the following criteria:
- •[12]Have physical tumor symptoms
- •[13]Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
- •[14]Have evidence of central nervous system metastasis (routine screening is not necessary).
- •[15]Women who are pregnant or breastfeeding.
- •[16]Serious concomitant disorder, including active bacterial, fungal, or viral infection, incompatible with the study (at the discretion of the investigator).
- •[17]Second primary malignancy that could affect compliance with the protocol or interpretation of the results. Patients with adequately treated basal cell carcinoma of the skin or who have had another malignancy in the past, but have been disease-free for more than 2 years, are eligible.
- •[18]Electrocardiogram (ECG) abnormalities indicative of cardiac disease (at the discretion of the investigator).
- •[19]Uncorrected electrolyte disorder, including potassium <3.4 mmol/L (<3.4 mEq/L).
- •[20] Inability to swallow tablets.
- •[21] Are currently receiving phenytoin, phenobarbital or carbamazapine.
研究者
相似试验
进行中（未招募）
不适用
A Phase 2 Study of Oral Enzastaurin HCl in Patients with Metastatic Colorectal Cancer - N/Ametastatic colorectal cancerEUCTR2004-005068-26-SEEli Lilly and Company limited40
已完成
2 期
Oral Enzastaurin in Participants With Relapsed Mantle Cell LymphomaMantle-Cell LymphomaNCT00088205Eli Lilly and Company60
已完成
2 期
Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane ChemotherapyBreast NeoplasmsNCT00386087Eli Lilly and Company41
已完成
2 期
Enzastaurin for Patients With Metastatic Colorectal CancerColonic NeoplasmsNCT00192114Eli Lilly and Company28
进行中（未招募）
不适用
A Randomized Phase 3 Study of Enzastaurin versus Lomustine in the Treatment of Recurrent, Intracranial Glioblastoma Multiforme - N/AGlioblastomaEUCTR2005-004627-18-GBEli Lilly and Company Limited397